Grapefruit USA, Inc. (GPFT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGrapefruit USA, Inc. (GPFT) trades at $0.0002. Grapefruit USA, Inc. is a Delaware-based healthcare company focused on developing and distributing cannabis-related goods, primarily in California. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for GPFT: GPFT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Grapefruit USA, Inc. (GPFT) Healthcare & Pipeline Overview
Grapefruit USA, Inc. is a Delaware-based healthcare company specializing in the development and distribution of cannabis-related goods, primarily targeting the California market. Its flagship product, Hourglass, is a proprietary sustained-release THC and CBD topical cream, exclusively sold through its dedicated online platform, positioning the company within the evolving specialty cannabis sector.
What Is the Investment Thesis for GPFT?
Grapefruit USA, Inc. presents an investment profile centered on its participation in the specialized segment of the cannabis industry, specifically through its proprietary topical product, Hourglass. The company's focus on the California market, a significant and mature regulated cannabis economy, provides a foundational operating environment. The sustained-release THC and CBD topical cream, Hourglass, represents a differentiated product offering within the wellness and therapeutic cannabis space, potentially appealing to consumers seeking localized, non-ingestible cannabinoid delivery methods. Growth catalysts include the potential for increased market penetration of Hourglass within California through enhanced online sales strategies and brand recognition. Further opportunities could arise from the broader trend of increasing acceptance and legalization of cannabis products, which may facilitate future geographic expansion beyond California, contingent on regulatory developments. However, the company's current market capitalization of $0.00B and its OTC Other listing signify a highly speculative investment with inherent volatility and liquidity risks. The ability to secure adequate funding for operational expansion and product development, alongside successfully navigating the complex and evolving regulatory landscape of the cannabis industry, will be critical value drivers. Investors should closely monitor the company's financial performance, product development pipeline, and strategic initiatives to expand its market presence.
Based on FMP financials and quantitative analysis
GPFT Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap company with potentially high volatility.
- Beta: -0.09, suggesting a low correlation with broader market movements, though this can be highly variable for micro-cap OTC stocks.
- Dividend Yield: None, as the company does not currently distribute dividends.
- Product Focus: Specialization in Hourglass, a sustained-release THC and CBD topical cream, targeting a specific niche within the cannabis wellness market.
- Geographic Concentration: Primary operational focus on the California market, leveraging its established regulatory framework.
Who Are GPFT's Competitors?
GPFT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $5.03 | +56.21% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $11.4M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $20.9M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $21.9M | — |
| TXMD TherapeuticsMD, Inc. | $2.08 | +1.22% | $24.0M | — |
| CPHI CPHI | $0.67 | +1.57% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GPFT's Key Strengths?
Proprietary sustained-release THC and CBD topical cream (Hourglass).
- Exclusive online sales platform for direct consumer engagement.
- Focus on the large and established California cannabis market.
- Specialization in a niche segment (topical applications) of the cannabis industry.
What Are GPFT's Weaknesses?
Very low market capitalization ($0.00B) indicating limited financial resources.
- OTC Other listing, implying high volatility and limited liquidity.
- Reliance on a single flagship product (Hourglass) for revenue generation.
- Small employee base (9 employees) potentially limiting scalability and operational breadth.
What Are the Key Risks for GPFT?
Financial-distress signal — its Altman Z-Score of -31.29 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Funding and Liquidity Challenges: Given its $0.00B market capitalization and OTC Other listing, Grapefruit USA, Inc. faces significant challenges in securing adequate funding for operations, expansion, and product development, potentially leading to operational constraints or dilution.
- Regulatory Uncertainty in Cannabis Industry: The cannabis industry operates under a complex and evolving patchwork of state and federal regulations. Changes in these regulations, particularly at the federal level, could negatively impact the company's operations, market access, or product legality.
- Intense Competition: The cannabis market, even in specialized segments like topicals, is highly competitive with numerous players. Grapefruit USA, Inc. must continuously innovate and differentiate to maintain market share against existing and new entrants.
- Product Concentration Risk: The company's primary reliance on a single flagship product, Hourglass, exposes it to significant risk if demand for this product declines, or if competitors introduce superior alternatives.
- OTC Market Risks: The OTC Other listing inherently carries risks of low liquidity, high volatility, and limited transparency, making the stock highly speculative and potentially difficult to trade.
What Threats Does GPFT Face?
- Evolving and complex regulatory landscape in the cannabis industry.
- Intense competition from established and emerging cannabis companies.
- Difficulty in securing adequate funding for growth and operations due to low market cap.
- Potential for new, more effective topical cannabis products from competitors.
What Are GPFT's Competitive Advantages?
- Proprietary Formulation: The sustained-release blend of THC and CBD in Hourglass represents a unique product offering in the topical cannabis market.
- Direct-to-Consumer Channel: Exclusive online sales platform provides control over brand messaging, customer experience, and direct access to consumer data.
- Early Market Entry: Established in 2017, the company has some tenure in the evolving cannabis industry, particularly in California.
What Does GPFT Do?
Grapefruit USA, Inc., headquartered in Wilmington, Delaware, operates within the dynamic cannabis industry, focusing on the development, branding, and distribution of cannabis-related products. Established in 2017, the company initially operated under the name Grapefruit Boulevard Investments, Inc., before officially rebranding to its current corporate identity in January 2020. The core of Grapefruit USA's business model revolves around serving the California market, one of the largest and most established regulated cannabis markets globally. A significant offering in its product portfolio is Hourglass, a distinctive topical cream. This product is formulated with a sustained-release blend of Tetrahydrocannabinol (THC) and Cannabidiol (CBD), designed for localized application. The company leverages a direct-to-consumer strategy for Hourglass, distributing it exclusively through its dedicated online platform. With a lean operational structure, employing 9 individuals, Grapefruit USA, Inc. aims to carve out a niche in the specialty cannabis segment, particularly within the wellness and therapeutic applications of cannabinoids. Its strategic focus on a proprietary topical product and a specific geographic market underscores its approach to navigating the complex and evolving regulatory and competitive landscape of the cannabis sector. The company's evolution from its founding to its current structure reflects an adaptation to market demands and regulatory frameworks within the United States cannabis industry.
What Products and Services Does GPFT Offer?
- Develops and distributes cannabis-related goods.
- Specializes in creating topical cannabis products.
- Offers Hourglass, a proprietary sustained-release THC and CBD topical cream.
- Sells Hourglass exclusively through its dedicated online platform.
- Primarily serves the California market.
- Focuses on the wellness and therapeutic applications of cannabinoids.
- Operates as a drug manufacturer in the specialty and generic segment.
How Does GPFT Make Money?
- Product Development and Sales: Develops proprietary cannabis-infused topical creams, such as Hourglass, and generates revenue directly from their sale.
- Direct-to-Consumer (DTC) E-commerce: Utilizes an exclusive online platform for the distribution of its flagship product, bypassing traditional retail channels to reach customers directly.
- Niche Market Focus: Targets the specialty cannabis market, specifically consumers seeking topical applications of THC and CBD for localized effects.
What Industry Does GPFT Operate In?
Grapefruit USA, Inc. operates within the Healthcare sector, specifically categorized under Drug Manufacturers - Specialty & Generic, due to its focus on cannabis-related goods. The broader cannabis industry is characterized by rapid evolution, driven by increasing legalization trends at the state level in the U.S. and globally. This has led to significant market growth, with projections indicating continued expansion in both medical and recreational segments. Within this landscape, Grapefruit USA positions itself in the specialty segment, focusing on topical applications of cannabinoids rather than traditional ingestibles or inhalables. The competitive environment is fragmented, comprising numerous small to medium-sized enterprises alongside larger, more established multi-state operators (MSOs). Key market trends include a growing consumer preference for diverse product forms, including topicals, tinctures, and edibles, and an increasing emphasis on product formulation, efficacy, and consistent dosing. Grapefruit USA's strategy of offering a proprietary sustained-release topical cream, Hourglass, aims to differentiate it within this crowded market by addressing a specific consumer need for localized cannabinoid delivery. Its exclusive online sales channel further defines its competitive approach within the California market.
Who Are GPFT's Key Customers?
- Consumers in California seeking topical cannabis solutions for wellness or therapeutic purposes.
- Individuals interested in non-ingestible or non-inhalable forms of cannabinoid delivery.
- Customers who value sustained-release formulations for consistent product effects.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 12 sales, 0 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for Grapefruit USA, Inc. stands at 14.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -77.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -44.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Grapefruit USA, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.29 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Grapefruit USA, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Bradley J. Yourist. GPFT has traded publicly since 2016.
GPFT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
GPFT Latest News
No recent news available for GPFT.
GPFT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for GPFT.
Price Targets
Wall Street price target analysis for GPFT.
GPFT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for GPFT; grades run from A+ (80-100) to F (below 30).
Leadership: Bradley J. Yourist
Chief Executive Officer
Bradley J. Yourist serves as the Chief Executive Officer of Grapefruit USA, Inc., overseeing the company's strategic direction and day-to-day operations. His leadership is central to managing the company's small team of 9 employees and navigating its focus within the cannabis sector. His tenure involves guiding the company through its operational phases and market positioning.
Track Record: Under Bradley J. Yourist's leadership, Grapefruit USA, Inc. has focused its efforts on the development and distribution of its flagship product, Hourglass, a sustained-release THC and CBD topical cream. He has overseen the company's strategic decision to concentrate on the California market and to utilize an exclusive online platform for product sales. His track record includes managing the company's transition from Grapefruit Boulevard Investments, Inc. to its current name in January 2020 and maintaining operations within the highly regulated cannabis industry.
GPFT OTC Market Information
Grapefruit USA, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC market, distinct from regulated exchanges like the NYSE or NASDAQ. Companies on the OTC Other tier typically do not meet the minimum financial or disclosure requirements of higher OTC tiers (like OTCQB or OTCQX) or major exchanges. This tier is characterized by companies that may not be current in their reporting with a U.S. regulator, or that are in financial distress. It implies a higher degree of risk due to limited public information and less stringent oversight compared to companies listed on national exchanges.
- OTC Tier: OTC Other
- Limited public disclosure and transparency due to "Unknown" disclosure status.
- Extremely low liquidity and high volatility associated with the OTC Other tier.
- Potential for price manipulation and fraudulent activities due to minimal oversight.
- Difficulty in obtaining accurate and timely financial information for investment decisions.
- Higher risk of delisting or cessation of trading due to non-compliance or financial distress.
- Verify any available financial statements and audit reports directly from the company or third-party sources.
- Research management's background, experience, and track record beyond what is publicly stated.
- Assess the company's operational viability and revenue generation capabilities independently.
- Investigate any legal or regulatory actions against the company or its management.
- Understand the specific risks associated with the cannabis industry and OTC trading.
- Evaluate the company's capital structure and potential for dilution from future financings.
- Seek independent legal and financial advice before considering investment.
- Clear articulation of its business model and product (Hourglass) in the cannabis sector.
- Stated focus on the regulated California market, indicating adherence to state-level compliance.
- Identified CEO, Bradley J. Yourist, providing a named individual responsible for leadership.
- Established in 2017, suggesting some operational history, albeit under a previous name.
- Specific product offering (sustained-release THC/CBD topical) implies a degree of specialization.
Grapefruit USA, Inc. Healthcare Stock: Key Questions Answered
What is Grapefruit USA, Inc.'s primary business focus and product offering?
Grapefruit USA, Inc. is fundamentally dedicated to the creation and distribution of cannabis-related goods, with a specific emphasis on the California market.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data provided beyond market cap, beta, and dividend yield. Growth opportunities and risks are inferred from business description and industry context. Specific market sizes and timelines for growth opportunities are qualitative due to lack of explicit data.